期刊文献+

含CpG和CTB的HIV多表位基因真核表达载体的构建及表达

Construction and expression of eukaryotic expression vector of HIV multi-epitope gene containing CpG sequence and CTB gene
原文传递
导出
摘要 目的构建含非甲基化的CpG ODN序列及霍乱毒素B亚单位(CTB)的HIV复合多表位基因的真核表达载体,并在体外进行表达。方法设计并合成含CpG ODN序列和linker序列的CTB基因引物,用PCR方法扩增CpG-CTB基因(CC),定向连接到真核表达载体pVL上,然后在CC基因下游插入HIV复合多表位基因MEGNp24,构建重组质粒pVL-CC-MEGNp24,酶切鉴定。纯化重组质粒,转染293T细胞,RT-PCR和细胞免疫染色方法分别检测CTB和p24基因的转录及表达,同时设质粒pVL及空白对照。结果构建了重组质粒pVL-CC-MEGNp24,该质粒转染293T细胞后,CTB和复合多表位基因在293T细胞中得到稳定表达。结论成功构建了含免疫佐剂的HIV复合多表位真核表达载体,为后期疫苗的研究奠定了基础。 Objective To construct a eukaryotic expression vector of HIV multi-epitope gene containing unmethylated CpG ODN sequence and cholera toxin B subunit(CTB) and expression in vitro.Methods The primers of CTB gene containing CpG ODN and linker sequence were designed and synthesized.CpG-CTB gene sequence(CC) was obtained by PCR,and connected to pVL.HIV multi-epitope gene was inserted into the downstream of CC gene to construct pVL-CC-MEGNp24.The recombination plasmid was confirmed by enzyme digestion.293T Cells were transfected with the purified recombination plasmid pVL-CC-MEGNp24.The transcription of CTB and p24 gene in the transfected 293T cells was detected by RT-PCR,and the expression of CTB and p24 protein was confirmed by cellular immunostaining.The plasmid pVL and blank controls were established simultaneously.Results The results showed that the recombination plasmid of pVL-CC-MEGNp24 was constructed,and CTB and multi-epitope gene were stably expressed in the 293T cells transfected with the plasmid pVL-CC-MEGNp24.Conclusion The eukaryotic expression vector of HIV multi-epitope gene containing immunological adjuvants is successfully constructed,facilitating studies of HIV vaccine.
出处 《军事医学》 CAS CSCD 北大核心 2011年第3期180-183,共4页 Military Medical Sciences
基金 重大传染病专项(2008ZX10004-015) 军队"十一五"科技攻关项目(06G127) 吉林省高新技术产业发展项目(2010) 长春市科技特派员行动计划(09KT04)
关键词 CPG ODN CTB HIV多表位基因 RT-PCR 细胞免疫染色 CpG ODN CTB HIV multi-epitope gene RT-PCR cellular immunostaining
  • 相关文献

参考文献12

  • 1李太生.国内外艾滋病抗病毒治疗研究进展[J].传染病信息,2008,21(6):324-326. 被引量:24
  • 2L. G. Nemchinov,T. J. Liang,M. M. Rifaat,H. M. Mazyad,A. Hadidi,J. M. Keith.Development of a plant-derived subunit vaccine candidate against hepatitis C virus[J]. Archives of Virology . 2000 (12)
  • 3UNAIDS.AIDS epidemic update. (UNAIDS/09.36E/JC1700E) . 2009
  • 4Flynn NM,Forthal DN,Harro CD,et al.Placebo-controlled phase3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1infection. The Journal of Infectious Diseases . 2005
  • 5Klinman DM,Xie H,Ivins BE.CpG oligonucleotides improvethe protective immune response induced by the licensed anthraxvaccine. Annals of the New York Academy of Sciences . 2006
  • 6Tross D,Klinman DM.Effect of CpG oligonucleotides on vac-cine-induced B cell memory. J Immunol . 2008
  • 7Schnitzler AC,Burke JM,Wetzler LM.Induction of cell signalingevents by the cholera toxin b subunit in antigen-presenting cells. Infection and Immunity . 2007
  • 8Takeshita F,Leifer CA,Gursel I,et al.Cutting edge: role of Toll-like receptor 9 in cpg DNA-induced activation of human cells. Journal of Immunology . 2001
  • 9O Longo,A Tripiciano,V Fiorelli,S Bellino,A Scoglio,B Collacchi,MJ Alvarez,V Francavilla,A Arancio,G Paniccia,A Lazzarin,G Tambussi,CT Din,R Visintini,P Narciso,A Antinori,G D’Offizi,M Giulianelli,M Carta,A Carlo,G Palamara,M Giuliani,ME Laguardia,P Moni.Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine . 2009
  • 10Rerks-Ngarm S,Pitisuttithum P,Nitayaphan S, et al.Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The New England Journal of Medicine . 2009

二级参考文献15

  • 1Zhang F,Dou Z,Yu L,et ol. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China[J]. Clin Infect Dis, 2008,47(6):825- 833.
  • 2UNAIDS. AIDS epidemic Update 2007 [EB/OL]. [2008-09- 30]. http://www.unaids.org/wad2007/report.html.
  • 3Ho DD, Neumann AU, Perelson AS,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection [J]. Nature, 1995,373(6510):123-126.
  • 4Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection[J]. Nature, 1995, 373(6510):117-122.
  • 5Staszewski S, Morales-Ramirez J,Tashima KT,et al. Efavirenz plus zidovudine and lamivudine,efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treat- ment of HIV-1 infection in adults. Study 006 Team[J]. N Engl J Med, 1999,341(25):1865-1873.
  • 6Gallant JE, Staszewski S, Pozniak AL, et ol. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial[J]. JAMA, 2004,292(2):191-201.
  • 7Steigbigel R, Kumar P, Eron J, et al. Results from BENCH-MRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV- 1 integrase inhibitor, in patients with triple-class resistant virus[C/OL]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, February 25-28,2007. [2008-09-30]. http://www.retro- conference.org/2007/Abstracts/30688.htm.
  • 8Anton P, Morales-Ramirez J, Mohapi L, et al. 48-week primary analysis of trial TMC278-C204:TMC278 demonstrates potent and sustained efficacy in ART-naive patients[C/OL]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles,USA,February 25-28,2007.[2008-09- 30].http://www.retroconference.org/2007 /Abstracts/30659.htm.
  • 9Valdez-Madruga J, Berger DS, McMurchie M, et al. Comparison of 48-week efficacy and safety of darunavir/ritonavir (DRV/r) with lopinavir/ritonavir (LPV/r) in LPV/r-naive, treatment-experienced patients : a randomised, controlled phase III trial (TITAN) [C/OL].4th International AIDS Soci- ety Conference on HIV Pathogenesis, Treatment and Prevention, Sydney,Australia, July 22--25,2007. [2008-09-30]. http://www.natap.org/2OO7 /IAS/IAS_16.htm.
  • 10Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel[J]. JAMA, 2006,296(7): 827-843.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部